A 48-yr-old female presented for a scheduled left breast lumpectomy, axillary sentinel node dissection, and bilateral reduction mammoplasty
High-risk features at baseline: Prior symptomatic gallstones or biliary colic Existing asymptomatic stones on prior imaging Obesity (BMI 35), particularly in female patients over 40 Rapid prior weight loss history Crohn's disease or terminal ileal resection (impairs bile salt reabsorption) Family history of cholelithiasis Patients with prior symptomatic gallstones should discuss prophylactic cholecystectomy with a surgeon before starting semaglutide, or at minimum have a baseline ultrasound documented in the chart
Overall, PT-141 is generally considered safe when used in controlled, as-needed doses, but users should monitor tolerance and consult with a healthcare provider, especially if they have underlying health conditions
KLOW (Blend) Research Blend Overview KLOW is a high-purity, research-grade fourpeptide formulation that combines BPC157, TB500, KPV, and GHKCu into a single system for advanced investigation of tissue repair, inflammation control, dermal regeneration, and cellular signaling
The nucleus tractus solitarius (NTS) contains GLP-1 neurons that are activated by nicotine
